Cancer Vaccines After Melanoma: Which Tumors Are Next?

What has the personalized melanoma vaccine trial shown?

Personalized cancer vaccination has reached a major clinical milestone. On August 19, Merck and Moderna announced that the phase 3 INTerpath-001 trial met its main recurrence-free survival endpoint and a key endpoint measuring distant metastasis-free survival. The study evaluated intismeran autogene, also called V940 or mRNA-4157, with pembrolizumab in people whose stage IIB–IV cutaneous melanoma had been completely removed. The comparison group received pembrolizumab without the active vaccine. Overall survival remains under evaluation. These findings come from a sponsor announcement. [Merck and Moderna trial announcement](https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/)

On October 13, Merck said the first phase 3 presentation would take place at the European Society for Medical Oncology congress, scheduled for October 23–27. As of this article's publication, that presentation is still ahead. Its importance will extend beyond whether an endpoint was met: clinicians need the absolute difference between treatment groups, follow-up duration, adverse effects and results across disease stages. The announcement continues to describe intismeran as investigational; a successful trial does not itself establish regulatory approval or routine availability. [Merck's ESMO presentation announcement](https://www.merck.com/news/merck-showcases-first-time-pivotal-phase-3-results-from-oncology-pipeline-and-continued-innovative-potential-of-existing-portfolio-at-esmo-2026/)

Which cancers could benefit from personalized vaccines next?

Pancreatic cancer provides an important test of whether vaccination can generate durable immunity. A phase 1 study combined surgery, the checkpoint inhibitor atezolizumab, the personalized vaccine autogene cevumeran and chemotherapy. Among 16 vaccinated participants, eight developed the measured vaccine-induced T-cell response. A Nature follow-up published in 2025 found that these immune responders had longer recurrence-free survival than nonresponders after a median 3.2 years of observation. However, this was a small study without a randomized unvaccinated comparison group. Differences between responders and nonresponders cannot establish how much benefit vaccination added to the other treatments. [Pancreatic cancer follow-up study](https://www.nature.com/articles/s41586-024-08508-4)

Triple-negative breast cancer offers another early signal. A Nature paper published in February 2026 described 14 evaluable patients who received individualized mRNA vaccination after surgery and standard treatment. Researchers detected vaccine-induced T-cell responses in nearly all participants, with functional responses persisting for years. The study supports the feasibility of creating lasting immune recognition, but its small, noncomparative design cannot demonstrate that the vaccine reduced recurrence. It also documented ways tumors could evade immune recognition, underscoring why an immune response may not always translate into disease control. [Triple-negative breast cancer vaccine study](https://www.nature.com/articles/s41586-025-10004-2)

The intismeran development program also includes trials in non-small cell lung cancer, bladder cancer and renal cell carcinoma. These are separate tests of clinical benefit: the melanoma findings cannot establish effectiveness in another tumor type. Each setting requires evidence that adding vaccination improves outcomes enough to justify its risks and treatment burden. [Intismeran development program](https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/)

How do personalized cancer vaccines work?

Researchers analyze tumor tissue to identify mutations that can produce distinctive protein fragments called neoantigens. An individualized mRNA vaccine carries instructions for making selected fragments, allowing immune cells to learn what to recognize. The intended result is a population of T cells capable of finding cancer cells displaying those targets. The National Cancer Institute explains that choosing effective targets and manufacturing a separate vaccine for each patient are central challenges. [NCI explanation of mRNA cancer vaccines](https://www.cancer.gov/news-events/cancer-currents-blog/2022/mrna-vaccines-to-treat-cancer)

These are treatment vaccines for people who have been diagnosed with cancer, including patients treated after surgery to address the risk of recurrence. Their purpose differs from preventive vaccination against infections associated with cancer. For patients considering participation in research, the practical questions include whether their cancer and treatment history match the study, what standard treatment they would receive, and what additional visits or side effects vaccination might involve. A personalized design does not guarantee an individual response. [NCI guide to cancer treatment vaccines](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines)